EMEA-001344-PIP02-17 - paediatric investigation plan

ezetimibe
Rosuvastatin
PIPHuman

Key facts

Invented name
  • Zenon
  • Suvezen
Active Substance
  • ezetimibe
  • Rosuvastatin
Therapeutic area
Cardiovascular diseases
Decision number
P/0126/2018
PIP number
EMEA-001344-PIP02-17
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Prevention of cardiovascular events
Route(s) of administration
Oral use
Contact for public enquiries

Zentiva, k.s.

Czech Republic
blanka.zoubkova@zentiva.com
Tel. +42 0267243574

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page